Meyka AI API is live for developers.Start building.
Advertisement
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKSNASDAQ
HealthcareBiotechnology
$42.80
$0.58(1.34%)
U.S. Market opens in 54h 20m
Advertisement

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap7.1B
P/E Ratio46.42
EPS (TTM)$0.90
ROE0.09%
Fundamental Analysis

AI Price Forecasts

1 Month$27.00
3 Months$27.57
1 Year Target$30.20

ALKS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alkermes plc (ALKS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 71.08, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $30.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 46.42 and a market capitalization of 7.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.34%
5-Day Change
7.00%
1-Month Change
18.07%
3-Month Change
50.97%
6-Month Change
44.99%
Year-to-Date (YTD) Change
52.97%
1-Year Change
38.06%
3-Year Change
45.28%
5-Year Change
82.13%
All-Time (Max) Change
678.18%

Contact Information

353 1 772 8000
Connaught House, Dublin, NaN, 4

Company Facts

1,800 Employees
IPO DateJul 16, 1991
CountryUS
Actively Trading

Frequently Asked Questions